101 related articles for article (PubMed ID: 1713038)
1. Treatment of gastrointestinal endocrine tumours with interferon-alpha and octreotide.
Creutzfeldt W; Bartsch HH; Jacubaschke U; Stöckmann F
Acta Oncol; 1991; 30(4):529-35. PubMed ID: 1713038
[TBL] [Abstract][Full Text] [Related]
2. Single dose of octreotide stabilize metastatic gastro-entero-pancreatic endocrine tumours.
Angeletti S; Corleto VD; Schillaci O; Moretti A; Panzuto F; Annibale B; Delle Fave G
Ital J Gastroenterol Hepatol; 1999; 31(1):23-7. PubMed ID: 10091100
[TBL] [Abstract][Full Text] [Related]
3. Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumours.
Kölby L; Persson G; Franzén S; Ahrén B
Br J Surg; 2003 Jun; 90(6):687-93. PubMed ID: 12808615
[TBL] [Abstract][Full Text] [Related]
4. Combination therapy with octreotide and alpha-interferon: effect on tumor growth in metastatic endocrine gastroenteropancreatic tumors.
Frank M; Klose KJ; Wied M; Ishaque N; Schade-Brittinger C; Arnold R
Am J Gastroenterol; 1999 May; 94(5):1381-7. PubMed ID: 10235222
[TBL] [Abstract][Full Text] [Related]
5. Long-term management of the carcinoid syndrome. Treatment with octreotide alone and in combination with alpha-interferon.
Janson ET; Oberg K
Acta Oncol; 1993; 32(2):225-9. PubMed ID: 7686765
[TBL] [Abstract][Full Text] [Related]
6. Prospective study of the antitumor efficacy of long-term octreotide treatment in patients with progressive metastatic gastrinoma.
Shojamanesh H; Gibril F; Louie A; Ojeaburu JV; Bashir S; Abou-Saif A; Jensen RT
Cancer; 2002 Jan; 94(2):331-43. PubMed ID: 11900219
[TBL] [Abstract][Full Text] [Related]
7. Interferon treatment in patients with malignant carcinoids.
Nobin A; Lindblom A; Månsson B; Sundberg M
Acta Oncol; 1989; 28(3):445-9. PubMed ID: 2742782
[TBL] [Abstract][Full Text] [Related]
8. Octreotide improves biochemical, radiologic, and symptomatic indices of gastroenteropancreatic neoplasia in patients with multiple endocrine neoplasia type 1 (MEN-1). Implications for an integrated model of MEN-1 tumorigenesis.
Burgess JR; Greenaway TM; Parameswaran V; Shepherd JJ
Cancer; 1999 Nov; 86(10):2154-9. PubMed ID: 10570446
[TBL] [Abstract][Full Text] [Related]
9. [Combined treatment of metastatic endocrine tumors of the gastrointestinal tract with octreotide and interferon-alpha].
Nold R; Frank M; Kajdan U; Trost U; Klose KJ; Arnold R
Z Gastroenterol; 1994 Apr; 32(4):193-7. PubMed ID: 7517086
[TBL] [Abstract][Full Text] [Related]
10. Liver embolizations of patients with malignant neuroendocrine gastrointestinal tumors.
Eriksson BK; Larsson EG; Skogseid BM; Löfberg AM; Lörelius LE; Oberg KE
Cancer; 1998 Dec; 83(11):2293-301. PubMed ID: 9840528
[TBL] [Abstract][Full Text] [Related]
11. Treatment of malignant midgut carcinoid with a highly purified human leukocyte alpha-interferon.
Ahren B; Engman K; Lindblom A
Anticancer Res; 1992; 12(1):129-33. PubMed ID: 1567158
[TBL] [Abstract][Full Text] [Related]
12. [Neuroendocrine tumors of the pancreas and gastrointestinal tract].
Höring E; von Gaisberg U
Dtsch Med Wochenschr; 1991 Aug; 116(31-32):1197-202. PubMed ID: 1677619
[No Abstract] [Full Text] [Related]
13. Use of octreotide in the treatment of digestive neuroendocrine tumours. Seven year experience in 20 cases including 9 cases of metastatic midgut carcinoid and 5 cases of metastatic gastrinoma.
Fiasse R; Pauwels S; Rahier J; Jamar F; Ketelslegers JM; Hassoun A; de Longueville M
Acta Gastroenterol Belg; 1993; 56(3-4):279-91. PubMed ID: 8266771
[TBL] [Abstract][Full Text] [Related]
14. [Malignancy: treatment and prognosis of gastrointestinal and pancreatic endocrine neoplasia: retrospective study of a series of 16 cases].
Pansini GC; Lanzara S; Feo CV; Zamboni P; Liboni A; Ambrosio MR; Marzola A; Feggi L
Ann Ital Chir; 2001; 72(4):413-21; discussion 422. PubMed ID: 11865693
[TBL] [Abstract][Full Text] [Related]
15. Interferon alpha therapy for patients with essential thrombocythemia: final results of a phase II study initiated in 1986.
Saba R; Jabbour E; Giles F; Cortes J; Talpaz M; O'Brien S; Freireich EJ; Garcia-Manero G; Kantarjian H; Verstovsek S
Cancer; 2005 Jun; 103(12):2551-7. PubMed ID: 15861412
[TBL] [Abstract][Full Text] [Related]
16. [A prolonged-action somatostatin analog and carcinoid syndrome].
Chayvialle JA
Bull Acad Natl Med; 1989 May; 173(5):643-50; discussion 650-1. PubMed ID: 2478266
[TBL] [Abstract][Full Text] [Related]
17. Clinical outcome of a cohort of 63 patients with hepatocellular carcinoma treated with octreotide.
Rabe C; Pilz T; Allgaier HP; Halm U; Strasser C; Wettstein M; Sauerbruch T; Caselmann WH
Z Gastroenterol; 2002 Jun; 40(6):395-400. PubMed ID: 12055662
[TBL] [Abstract][Full Text] [Related]
18. [Treatment of gastrointestinal neuroendocrine tumors with the somatostatin analog octreotide (Sandostatin)].
Stöckmann F; Creutzfeldt W
Z Gastroenterol; 1988 Oct; 26(10):665-75. PubMed ID: 2849248
[TBL] [Abstract][Full Text] [Related]
19. Recombinant alpha-2b interferon in patients with malignant carcinoid tumour.
Basser RL; Lieschke GJ; Sheridan WP; Fox RM; Green MD
Aust N Z J Med; 1991 Dec; 21(6):875-8. PubMed ID: 1726359
[TBL] [Abstract][Full Text] [Related]
20. Octreotide and interferon alfa: a new combination for the treatment of malignant carcinoid tumours.
Tiensuu Janson EM; Ahlström H; Andersson T; Oberg KE
Eur J Cancer; 1992; 28A(10):1647-50. PubMed ID: 1382492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]